[HTML][HTML] Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
K Bok, S Sitar, BS Graham, JR Mascola - Immunity, 2021 - cell.com
The development of effective vaccines to combat infectious diseases is a complex multi-year
and multi-stakeholder process. To accelerate the development of vaccines for coronavirus …
and multi-stakeholder process. To accelerate the development of vaccines for coronavirus …
[HTML][HTML] Features, evaluation, and treatment of coronavirus (COVID-19)
M Cascella, M Rajnik, A Aleem, SC Dulebohn… - 2020 - europepmc.org
Objectives: Screen individuals based on exposure and symptom criteria to identify potential
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …
[HTML][HTML] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone
progressive change, with variants conferring advantage rapidly becoming dominant …
progressive change, with variants conferring advantage rapidly becoming dominant …
[HTML][HTML] Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)
A Aleem, AS Ab, AK Slenker - 2021 - europepmc.org
Objectives: Describe the clinical manifestations, including extrapulmonary manifestations of
COVID-19. Outline the latest treatments available in the management of COVID-19 …
COVID-19. Outline the latest treatments available in the management of COVID-19 …
[HTML][HTML] Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals
The emergence of SARS-CoV-2 variants with evidence of antibody escape highlight the
importance of addressing whether the total CD4+ and CD8+ T cell recognition is also …
importance of addressing whether the total CD4+ and CD8+ T cell recognition is also …
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
KJ Bruxvoort, LS Sy, L Qian, BK Ackerson, Y Luo… - bmj, 2021 - bmj.com
Objectives To evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2
variants and assess its effectiveness against the delta variant by time since vaccination …
variants and assess its effectiveness against the delta variant by time since vaccination …
[HTML][HTML] SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast-
derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis
WY Au, PPH Cheung - Bmj, 2022 - bmj.com
Objective To evaluate the effectiveness of heterologous and homologous covid-19 vaccine
regimens with and without boosting in preventing covid-19 related infection, hospital …
regimens with and without boosting in preventing covid-19 related infection, hospital …
Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26. COV2. S COVID-19 vaccines
V Naranbhai, WF Garcia-Beltran… - The Journal of …, 2022 - academic.oup.com
Background Understanding immunogenicity and effectiveness of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical to guide rational use. Methods …
syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical to guide rational use. Methods …
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire
PA Swanson, M Padilla, W Hoyland… - Science translational …, 2021 - science.org
AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus–vectored vaccine,
has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 in …
has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 in …